JP6557235B2 - ｄｅ ｎｏｖｏ脂質生成のバイオマーカーおよびその使用方法 - Google Patents

ｄｅ ｎｏｖｏ脂質生成のバイオマーカーおよびその使用方法 Download PDF

Info

Publication number
JP6557235B2
JP6557235B2 JP2016541152A JP2016541152A JP6557235B2 JP 6557235 B2 JP6557235 B2 JP 6557235B2 JP 2016541152 A JP2016541152 A JP 2016541152A JP 2016541152 A JP2016541152 A JP 2016541152A JP 6557235 B2 JP6557235 B2 JP 6557235B2
Authority
JP
Japan
Prior art keywords
dnl
levels
biomarker
level
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016541152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500567A5 (enExample
JP2017500567A (ja
Inventor
ワトキンス、スティーブン、エム．
Original Assignee
メタボロン，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メタボロン，インコーポレイテッド filed Critical メタボロン，インコーポレイテッド
Publication of JP2017500567A publication Critical patent/JP2017500567A/ja
Publication of JP2017500567A5 publication Critical patent/JP2017500567A5/ja
Application granted granted Critical
Publication of JP6557235B2 publication Critical patent/JP6557235B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7057—(Intracellular) signaling and trafficking pathways
    • G01N2800/7066—Metabolic pathways
    • G01N2800/7085—Lipogenesis or lipolysis, e.g. fatty acid metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2016541152A 2013-12-20 2014-12-18 ｄｅ ｎｏｖｏ脂質生成のバイオマーカーおよびその使用方法 Active JP6557235B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361918866P 2013-12-20 2013-12-20
US61/918,866 2013-12-20
US201461934033P 2014-01-31 2014-01-31
US61/934,033 2014-01-31
PCT/US2014/071035 WO2015095451A1 (en) 2013-12-20 2014-12-18 Biomakers of de novo lipogenesis and methods using the same

Publications (3)

Publication Number Publication Date
JP2017500567A JP2017500567A (ja) 2017-01-05
JP2017500567A5 JP2017500567A5 (enExample) 2018-02-01
JP6557235B2 true JP6557235B2 (ja) 2019-08-07

Family

ID=53403674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016541152A Active JP6557235B2 (ja) 2013-12-20 2014-12-18 ｄｅ ｎｏｖｏ脂質生成のバイオマーカーおよびその使用方法

Country Status (9)

Country Link
US (1) US20160356798A1 (enExample)
EP (1) EP3082833B1 (enExample)
JP (1) JP6557235B2 (enExample)
AU (1) AU2014364539B2 (enExample)
CA (1) CA2933571A1 (enExample)
ES (1) ES2708807T3 (enExample)
MX (1) MX2016008045A (enExample)
SG (1) SG11201604702YA (enExample)
WO (1) WO2015095451A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105400732A (zh) * 2015-11-19 2016-03-16 南京理工大学 一种酒精性脂肪肝斑马鱼模型的构建方法
JP6992057B2 (ja) 2016-06-10 2022-01-13 クラリティ コスメティックス インコーポレイテッド 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
US11709169B2 (en) * 2017-02-07 2023-07-25 National Jewish Health Lipid abnormalities and association with atopic allergic diseases
EP3602605A4 (en) * 2017-03-31 2020-12-30 Metabolon, Inc. FULL AND QUANTITATIVE ANALYSIS OF LIPIDS AND TOCOPHEROLS
US11642300B2 (en) 2019-05-15 2023-05-09 Johnson & Johnson Consumer Inc. Method of selecting skin treatment regimens, ingredients and compositions
US20220142560A1 (en) 2020-11-06 2022-05-12 Johnson & Johnson Consumer Inc. Microbiome and metobolome clusters to evaluate skin health

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438420B1 (en) * 2001-09-24 2009-09-16 Lipomics Technologies, Inc. Methods of using quantitative lipid metabolome data
JP4682980B2 (ja) * 2004-04-23 2011-05-11 味の素株式会社 非アルコール性脂肪肝炎鑑別方法
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
CN102317786A (zh) * 2007-04-18 2012-01-11 特提斯生物科学公司 糖尿病相关性生物学标记物及其使用方法
WO2010028336A2 (en) * 2008-09-08 2010-03-11 President And Fellows Of Harvard College Fatty acid c16:1n7-palmitoleate a lipokine and biomarker for metabolic status
WO2012040318A2 (en) * 2010-09-23 2012-03-29 University Of Miami Compositions, methods and kits for detecting melanoma and margins of melanoma

Also Published As

Publication number Publication date
SG11201604702YA (en) 2016-07-28
WO2015095451A1 (en) 2015-06-25
US20160356798A1 (en) 2016-12-08
CA2933571A1 (en) 2015-06-25
ES2708807T3 (es) 2019-04-11
JP2017500567A (ja) 2017-01-05
AU2014364539B2 (en) 2019-08-01
AU2014364539A1 (en) 2016-06-16
EP3082833B1 (en) 2018-12-05
EP3082833A1 (en) 2016-10-26
EP3082833A4 (en) 2017-08-09
MX2016008045A (es) 2016-10-12

Similar Documents

Publication Publication Date Title
JP6557235B2 (ja) ｄｅ ｎｏｖｏ脂質生成のバイオマーカーおよびその使用方法
Tsimikas et al. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients
Steptoe et al. Associations between acute lipid stress responses and fasting lipid levels 3 years later.
Lee et al. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects
Ilias et al. Adipose tissue lipolysis and circulating lipids in acute and subacute critical illness: effects of shock and treatment
Kim et al. Comparison of epicardial, abdominal and regional fat compartments in response to weight loss
Mishra et al. Lipidomic architecture shared by subclinical markers of osteoporosis and atherosclerosis: The Cardiovascular Risk in Young Finns Study
JP6158186B2 (ja) インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
Chen et al. The association of metabolic syndrome and its components with brachial-ankle pulse wave velocity in south China
Li et al. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9
US20150011424A1 (en) Method for determining liver fat amount and method for diagnosing nafld
Notarnicola et al. Significant decrease of saturation index in erythrocytes membrane from subjects with non-alcoholic fatty liver disease (NAFLD)
Gander et al. Metabolic impairment in coronary artery disease: elevated serum acylcarnitines under the spotlights
KR101598597B1 (ko) 혈장 대사체를 이용한 고-ldl-콜레스테롤 질환 진단 장치 및 방법
Djekic et al. Metabolomics in atherosclerosis
Kishino et al. Visceral fat thickness in overweight men correlates with alterations in serum fatty acid composition
Schmidt et al. High apoB/apoA-I ratio is associated with increased progression rate of carotid artery intima-media thickness in clinically healthy 58-year-old men: experiences from very long-term follow-up in the AIR study
Peltier et al. Elevated serum lipoprotein (a) level is an independent marker of severity of thoracic aortic atherosclerosis
Hyun et al. Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men
US20250362315A1 (en) Quantification of lipoprotein subfraction by ion mobility
KR20160002495A (ko) 간 효소 및 혈장 대사체를 이용한 심혈관 질환의 예측 또는 진단 방법
Vaidya et al. Skin tissue cholesterol assay correlates with presence of coronary calcium
HK1224920A1 (en) Biomarkers of de novo lipogenesis and methods using the same
HK1224920B (en) Biomarkers of de novo lipogenesis and methods using the same
Hirayama et al. Fasting serum free glycerol concentration is a potential surrogate marker of visceral obesity and insulin sensitivity in middle-aged Japanese men

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190711

R150 Certificate of patent or registration of utility model

Ref document number: 6557235

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250